Congratulations to AiM Medical Robotics for their successful $8.1 million Series A financing round. This major achievement, led by IQ Capital and 1540 Ventures, marks an exciting step forward for their groundbreaking MRI-compatible robotic platform. By combining deep clinical expertise and advanced engineering, AiM’s MRI-compatible robotic platform enables real-time, image-guided precision for surgeries treating conditions like Parkinson’s disease, epilepsy, and cancer. With this innovative technology, AiM is helping usher in a new era of safer procedures, improved patient outcomes, and tangible workflow efficiency benefits for hospitals and surgical teams worldwide.
Kudos to the entire AiM team and their world-class investors for driving technological progress in neurosurgical robotics and setting new standards for patient care and minimally invasive medicine.
Triple Ring’s CEO, Joe Heanue, was featured in a white paper authored by Glenn Snyder, MedTech Practice Founder and Partner at Monitor Deloitte. The article revisits and updates a topic that Deloitte has been monitoring since 2017 – The disruption and evolution of investment in early-stage medical technology. In the MedTech innovation landscape, startups are increasingly caught in a precarious position—trapped between early funding rounds and the long, challenging journey of developing a market-ready product. This journey can span a decade or more, with financial, regulatory, and reimbursement hurdles adding layers of risk and uncertainty. To navigate this environment, alternative financing models such as build-to-buy are emerging as promising solutions. Under this model, a strategic MedTech company agrees to acquire a startup—or its assets—at a predetermined price once certain milestones are reached. For large MedTech (and Life Science) corporations, outsourcing innovation to a startup can create an off-the-balance-sheet way to fund innovation – avoiding internal R&D expenses and protecting EBITDA. For startups, these structures help derisk funding, provide access to market expertise, access to manufacturing and commercialization teams, and provide a possible path to exit.
To check in on this evolving investment landscape, Deloitte interviewed 16 leaders from VC, PE, CVC firms, and strategic investors, focusing on five critical topics shaping medtech financing today. These insights underscore the growing recognition of alternative financing models and their role in supporting early-stage medtech companies through a complex commercialization journey.
The white paper can be found by clicking this link
Triple Ring partner and client, Canaery has been featured in a Wired Magazine article about their breakthrough Nose to Computer Interface technology. The article describes the company’s partnership with the US Department of Energy to harness the mammalian olfactory system to detect and monitor compounds in air. The approach enables users to decode odors that an animal smells in real time and gather critical information about hazards, threats, and contraband. We congratulation Canaery on the article and are proud to have worked alongside the team to create this amazing technology.
Today Heartbeam Inc., a Silicon Valley based medical device company, announced FDA 510(k) clearance of the HeartBeam system – the only cable-free, credit card-sized device that captures patient heart signals to provide comprehensive arrhythmia assessment.
HeartBeam’s system is a synthesized 12-lead ECG integrated with AI-based classification algorithms for heart attack detection, allowing physicians to detect non-life-threatening arrhythmias for patients in the clinic or at home. Physicians are able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility
Triple Ring is proud to have partnered with HeartBeam in the design and development of this cutting edge platform which redefines the future of cardiac health management. We congratulate HeartBeam on this critical milestone and look forward to more breakthroughs in the future.
Congratulations to our Agility Labs member, CytoTronics, on closing $9.25 Million in seed funding, led by Anzu Partners with participation from Milad Alucozai (BoxOne Ventures) and institutional investors, to revolutionize drug discovery and phenotypic screening. Triple Ring is proud to be a part of the journey to provide the facility, technology, and mentorship support to CytoTronics from the very beginning. If you are interested in learning about CytoTronics and its complementary metal-oxide-semiconductor (CMOS)-powered drug discovery platform, please visit https://cytotronics.com/. If you are looking for a lab space to launch your innovative business, Agility Labs offers a flexible incubator for emerging life sciences, medical device, and technology companies in Silicon Valley and Boston. For more information, please visit our website at https://www.agilitylabs.org/ or email your inquiries to info@tripleringtech.com.
One Health Group and Triple Ring Technologies Partnership and Investment
SYRACUSE, NY, UNITED STATES, February 1, 2022 /EINPresswire.com/ — One Health Group, specializing in remote medical diagnostics for animal health, and Triple Ring Technologies announce that Triple Ring will serve as a technology partner, leading One Health Group’s product development effort, and providing the science and engineering team. Additionally, Triple Ring will make an investment in the One Health Group.
“Our technology partnership with Triple Ring will enable us to much more quickly bring our patented mobile health monitoring technology to market, and will support our goals as we build on our noncontact intelligent biometric sensing Voyce platform, bringing new, innovative physiological monitoring capabilities to support in-situ and real-time animal health care”, stated Al DiRienzo, CEO and Co-Founder of One Health Group.
One Health Group’s Voyce is the first non-invasive, remote digital device with patented algorithms that accurately monitors biometric data for better interventions in animal care. One Health Group’s technology is a huge leap forward for interconnectivity between animal, human and environmental impacts on health. OHG has partnered with world-leading academic institutions and prestigious medical technology companies to continue to build on its biometric monitoring platform to provide health diagnostics globally.
“Triple Ring is pleased to partner with One Health Group to develop the next version of their exciting platform for next-generation remote animal health monitoring. We believe in One Health Group and are taking a stake in the company, showing our support for their technology and the potential for the Voyce platform”, added Joe Heanue, CEO of Triple Ring Technologies.
About One Health Group: One Health Group (OHG) is a medical technology innovator with a mission to bring breakthrough health diagnostics, therapeutics, monitoring, screening, and advanced analytics to market. Driven by seeking solutions to preventing needless animal and human illnesses, often attributable by a lack of health data, OHG has developed a patented mobile health assessment technology that uses intelligent sensors and artificial intelligence to provide personalized, context-based real-time health information. OHG’s goal is to provide a unique health platform that integrates animal, human, and environmental data, which are intrinsically linked. For more information, please visit www.onehealthgroup.com.
About Triple Ring Technologies: Triple Ring Technologies is a co-development company headquartered in Silicon Valley, with offices in Boston, Toronto, and Copenhagen. They partner with clients in medtech, life sciences, and sustainability & the environment to create new technologies, launch innovative projects, and start new ventures. Their capabilities span early R&D, product development, manufacturing, regulatory approval, market access, strategic investment, and incubation. For more information, please visit www.tripleringtech.com.
To read the full press release, please click here.
Triple Ring Technologies and Woods Hole Oceanographic Institution (WHOI) are collaborating to fill an unmet need in environmental sensing – providing a fieldable, portable microplastic sensor that quantifies the number of plastic particles in water. A comprehensive understanding of microplastic pollution is significantly hampered by the unavailability of low-cost, robust, accurate, and rapid analysis techniques. There is an urgent need for such measurement information, to inform the public and policy makers, and toward developing and managing effective mitigation strategies for plastic pollution in the world’s water bodies. With readout available in minutes, the sensor will ensure that field sampling time is maximally productive while also usable in a lab environment to significantly speed up sample testing.
The core technology was developed at WHOI in the laboratory of Dr. Anna Michel, Associate Scientist, Department of Applied Ocean Physics and Engineering, with doctoral student Beckett Colson. Developing the proof-of-concept into a rugged, fieldable unit is being performed by Triple Ring Technologies under the leadership of Dr. Sheila Hemami, Sr. Director of Growth Initiatives. To further develop the technology, Triple Ring Technologies has been awarded an SBIR Phase I grant by the Environmental Protection Agency entitled “A fieldable, portable, reagent-free microplastic sensor enabling rapid readout and modular operation” and will work with WHOI to execute the grant.
Drs. Hemami and Michel believe that this new tool will allow easy, widespread assessment of microplastic pollution in waterways, wastewater, stormwater, and other applications in which the presence of microplastics is a concern. “Combining WHOI’s core sensing technology with Triple Ring’s experience in delivering integrated products will significantly move the needle on the understanding of microplastic pollution and will drive data-based mitigation solutions,” said Dr. Hemami.
Dr. Michel added “My lab is especially interested in developing technologies that enable us to robustly count the number of microplastics in drinking water, ponds, lakes, and oceans. We need field-deployable sensors that provide us this information in order for us to understand microplastic pollution.”
About Triple Ring Technologies
Triple Ring Technologies is a co-development company headquartered in Silicon Valley, with offices in Boston, Toronto, and Copenhagen. They partner with clients in medtech, life sciences, and sustainability & the environment to create new technologies, launch innovative projects, and start new ventures. Their capabilities span early R&D, product development, manufacturing, regulatory approval, market access, strategic investment, and incubation. For more information, please visit www.tripleringtech.com.
About Woods Hole Oceanographic Institution
The Woods Hole Oceanographic Institution (WHOI) is a private, non-profit organization on Cape Cod, Massachusetts, dedicated to marine research, engineering, and higher education. WHOI’s pioneering discoveries stem from an ideal combination of science and engineering. WHOI is known for its multidisciplinary approach, superior ship operations, and unparalleled deep-sea robotics capabilities. For more information, please visit www.whoi.edu.
To read the full press release, please click here.
Triple Ring is thrilled to announce that we have been awarded an SBIR Phase I grant by the Environmental Protection Agency entitled A fieldable, portable, reagent-free microplastic sensor enabling rapid readout and modular operation. This project is led by our Senior Director for Growth Initiatives, Dr. Sheila Hemami.
We are excited to be applying our deep technical and scientific expertise in support of our commitment to sustainability and the environment.
Triple Ring Technologies is pleased to announce that it is now operating in Copenhagen, Denmark, and Toronto, Ontario, Canada. These two new locations are key to supporting Triple Ring’s clients throughout Europe and North America, and furthering the company’s reach as a top-tier Medical Device & Life Sciences co-development partner.
Triple Ring believes Denmark’s healthcare innovation ecosystem, built around world-class academic institutions, biopharmaceutical and medical technology industries, and tightly aligned hospital system, make it an ideal location to support the European market. The company has forged strong relationships with the Danish government, industry innovators, and academic institutions and their incubator facilities. Triple Ring has also hosted the US-Denmark MedTech Partnership Conference in Copenhagen and Silicon Valley, and plans to resume the conference series when conditions permit.
“We are very excited to have established Triple Ring’s presence in Copenhagen this year and look forward to growing our business into Scandinavia and the European Union,” said Christina Pedersen, Vice President of Projects. “This is an ideal base of operations for Triple Ring as we bring our world class co-development services to the continent.”
The Toronto, Ontario region is another dynamic healthcare innovation hub in which Triple Ring is excited to participate. Toronto has established an excellent technology development and investment community, with particular strengths in artificial Intelligence, by combining the efforts of government, academia, and industry. Triple Ring aims to contribute to the growth of this ecosystem through partnerships with top universities, major research hospitals, life science and medical device companies, and investment organizations. The company has already begun relationships with pioneers in the region, and it looks to continue to grow its presence in the ecosystem.
“It is gratifying to see Triple Ring’s international footprint grow, particularly in these two important geographies,” said Joe Heanue, CEO of Triple Ring. “We are excited by the opportunities this expansion provides in bringing critical innovation services to the medical device and life sciences industries.”
Scientists from Triple Ring’s Photonics, Imaging, and X-Ray (PIX) team contributed to the paper, “Inverse treatment planning for an electronic brachytherapy system delivering anisotropic radiation therapy“, accepted in peer-reviewed journal Physics in Medicine and Biology, and published on IOPscience. The paper details the inverse radiation treatment planning algorithm which the team designed for Sensus Healthcare’s Sculptura™ electronic brachytherapy system.
Other contributors were Sensus Healthcare’s Chief Technology Officer Russ Price, Chief Operating Officer Nicolas Soro, and former Chief Technology Officer Kalman Fishman.
Read in its entirety here.